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Abstract 
Objective: The GRADE approach to rating certainty of evidence includes five 
domains of reasons for rating down certainty.  Only one of these, precision, is 
easily amenable – through the confidence interval – to quantitation.  The other 
four (risk of bias, inconsistency, indirectness, publication bias) are not.  
Nevertheless, conceptually, one could consider a quantified “certainty range” 
within which the true effect lies.  The certainty range would be at least as wide as 
the confidence interval, and would expand with each additional reason for 
uncertainty. 
Study Design and Setting: We have applied this concept to rating the certainty 
of evidence in the baseline risk of venous thromboembolism (VTE) and bleeding 
in patients undergoing urological surgery.  We considered rating up moderate or 
low quality evidence when the net benefit of VTE prophylaxis was unequivocally 
positive: that is, when the smallest plausible value of VTE reduction was greater 
than the largest plausible value of increased bleeding. To establish whether there 
the net benefit was unequivocally positive, we expanded the range of plausible 
values by 20% for each of the four non-quantitative domains in which there were 
serious limitations.  
Results: We present how we applied these methods to examples of open radical 
cystectomy and laparoscopic partial nephrectomy.  In high VTE risk laparoscopic 
partial nephrectomy patients and high- and medium VTE risk open radical 
cystectomy patients, results proved robust to expanded certainty intervals, 
justifying rating up quality of evidence.  In low risk patients, the results were not 
robust, and rating up was therefore not appropriate. 
Conclusion: This work represents the first empirical application in a decision-
making context of the previously suggested concept of certainty ranges and 
should stimulate further exploration of the associated theoretical and practical 
issues. 
Key words: GRADE; guidelines; quality of evidence; systematic reviews; 
thresholds; thromboprophylaxis 
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What is new? 
Key findings 
• This study represents a first foray into utilizing the concept of the 
certainty range to place a quantitative estimate on domains of 
uncertainty (risk of bias, inconsistency, indirectness, publication 
bias) that are up to now addressed only qualitatively.    
• We applied quantitative estimates to the baseline risks of venous 
thromboembolism and major bleeding in patients undergoing 
urological surgery and in doing so established whether inferences 
regarding the net benefits of pharmacologic prophylaxis were 
secure.   
 
What this adds to what was known? 
• The GRADE approach to rating certainty of evidence includes five 
domains of reasons for rating down certainty.  Only one of these, 
precision, is easily amenable – through the confidence interval – to 
quantitation.  The other four (risk of bias, inconsistency, 
indirectness, publication bias) are not.  
• This work highlights the concept of the uncertainty range and the 
potential for ultimate quantitation of all domains of uncertainty.   
 
What is the implication and what should change now? 
• This is the first empirical application in a decision-making context of 
the previously suggested concept of certainty ranges  
• This work should stimulate further exploration of the associated 
theoretical and practical issues to take these concepts forward. 
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Introduction 
The widely used GRADE approach to rating certainty in evidence (synonyms 
quality or confidence in evidence) can be applied to a variety of questions in 
health care, including to alternative management strategies (1) and prognosis (2).  
In evaluating therapy questions, randomized trials start as high quality evidence; 
for prognosis, observational studies start as high quality evidence.  For both sorts 
of questions, five domains of limitations may result in rating down certainty. 
 
The uncertainty associated with one of these domains of limitations, imprecision, 
can be quantitated by examining confidence (for frequentist analysis) or credible 
(for Bayesian analysis) intervals.  The extent of uncertainty associated with the 
other four domains of limitations – risk of bias, inconsistency, indirectness, and 
publication bias - is, thus far, not fully amenable to quantitation (3).  In this article, 
we will use the term “certainty range” to characterize uncertainty that considers 
all these domains. 
 
Conceptually, each of the five limitations extend the range of uncertainty – the 
range of plausible true effect – around the best estimate of effect.  One could 
therefore picture the certainty range around that best estimate (3).  The width of 
the certainty range would depend on the extent of concerns regarding 
imprecision – captured in the confidence or credible interval – and the extent of 
concern regarding the other four domains (Figure 1) (3). 
 
 
Figure 1 depicts the certainty range – like the confidence interval – as 
symmetrical around the point estimate.  This need not be the case.  For instance, 
if one knew the likely direction of risk of bias, the certainty range could be 
asymmetrical, skewed in that direction (3). Furthermore, for studies of prognosis 
or baseline risk – the focus of this article – given that values can range only 
between 0% and 100%, low probabilities or risks are likely to be skewed to the 
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right (e.g. if the point estimate is 1%, the certainty range can only drop by 1% to 
0, while it will plausibly rise to substantially more than 1%).  
 
The extent to which concerns regarding the four, as of yet, non-quantitative 
domains of uncertainty widen the certainty range is highly speculative.  As a 
result, the notion of the certainty range has heretofore been largely theoretical.  
In the course of a recently completed project (4), we rated the certainty of 
evidence regarding the likelihood of thrombosis and bleeding following urological 
surgery. In doing so, we felt that, despite the speculative nature of the certainty 
range, it would be worth invoking the concept to help in applying the GRADE 
certainty of evidence rating.  We present the work here because it may be the 
first scientific publication to empirically apply the certainty range to the rating of 
GRADE quality of evidence. 
 
We have an important disclaimer: although two of the authors are co-chairs of 
the GRADE working group (HJS and GHG) this work is not a product of, nor has 
it been endorsed by, the GRADE working group.  Moreover, a number of the 
concepts presented here, and the way the concepts have been incorporated, go 
considerably beyond current GRADE guidance.  Thus, the current work 
represents an exploration of possible future directions in thinking about and 
rating certainty of evidence. 
 
 
Background of the Project 
Patients undergoing surgery are at risk of postsurgical deep venous thrombosis 
or pulmonary embolism (venous thromboembolism or VTE). VTE can be serious, 
and indeed fatal.  Thus, prophylaxis against VTE with anticoagulants, in 
particular heparinoids, has become popular. 
 
Unfortunately, pharmacologic prophylaxis is associated with an increased risk of 
bleeding – always a concern after any surgical procedure - which can also be 
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serious (in our definition, requiring reoperation) and even fatal.  Thus, the 
decision regarding prophylaxis involves a tradeoff between reduced risk of VTE 
and increased risk of bleeding.  That trade off depends on both the risk of VTE 
and bleeding in the absence of prophylaxis (which we will call the baseline risk) 
and the relative decrease in VTE and increase in bleeding with prophylaxis. 
 
As part of a team charged with developing guidelines for prophylaxis after 
urological surgery (4), we undertook a series of systematic reviews to estimate 
the baseline risk of both VTE and bleeding (5-7).  We interpreted our results in 
the context of its implications for pharmacologic prophylaxis after major urological 
procedures. 
 
 
Methods and Results: Judging the Certainty of Baseline Risk Estimates 
Readers will find details of our methods in other articles (4-7).  In brief, we used 
rigorous systematic review methods to identify, evaluate, and summarize 
observational studies addressing the risk of VTE and bleeding requiring 
reoperation following urological surgery in the absence of VTE prophylaxis.  Our 
evaluation included a risk of bias assessment for each individual study, including 
consideration of representativeness of the patient population, 
thromboprophylaxis documentation, data source, whether a majority of patient 
recruitment years were earlier or later than 2000, clear specification of duration of 
follow-up, and study type. In addition, we identified risk factors for VTE and 
classified patients as at low, medium, and high risk.   
 
We were interested in VTE and bleeding risk at 4 weeks, and if studies reported 
VTE risk at some other interval we modeled the VTE risk at 4 weeks on basis of 
data from large-scale population-based observational studies (8, 9) and bleeding 
risk on the basis of a large randomized trial (10). In doing so, we used a 
previously published approach (5) that demonstrates an approximately constant 
hazard of VTE up to 4 weeks (8, 9); bleeding risk, by contrast, is concentrated in 
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the first 4 days (10). The modeling was required to offer the most trustworthy 
estimates of the benefits and risks of anticoagulation over a period of four weeks. 
We applied the GRADE rating of certainty of evidence, and interpreted our 
results in the context of the decision regarding administration of prophylaxis.  
Best evidence suggests that heparinoids decrease the relative risk of VTE by 
approximately 50%, and increase the relative risk of bleeding by 50% (6-7).  We 
rated the certainty of the evidence regarding these relative risks as high, and in 
applying the quantitative estimates assumed no error.  A reasonable alternative 
would have applied some estimate of uncertainty (for instance, confidence 
intervals) to the relative effects.  Doing so would have widened all certainty 
ranges shown in the following presentation.  
 
The desirability of quantitating uncertainty for the 4 previously listed non-
quantitative domains arose when we found a possible large gradient between 
benefits (VTE reduction) and harm (bleeding requiring reoperation).  Let us say, 
for instance, that the baseline risk of VTE for a procedure was 10%.  Applying the 
relative risk reduction with pharmacologic prophylaxis of 50%, we calculate an 
absolute reduction in VTE of 5%.  Let us say the associated baseline risk of 
bleeding is 1%, with a relative increase of 50% with prophylaxis, and thus an 
absolute increase in risk of 0.5%.  Even applying a judgment we made that a 
bleed has twice the importance (disutility) of a VTE, this appears to be a situation 
in which prophylaxis is clearly indicated and recommended (benefit of 5%, 
importance-adjusted harm of only 1%). 
 
One solution to expressing the large net benefit might be to rate up the low 
certainty evidence to moderate, or moderate to high.  This approach would be 
consistent with GRADE’s definition of certainty of evidence relating to the extent 
to which the evidence supports a recommendation.  It goes, however, beyond 
current GRADE guidance in applying this definition to judgments regarding 
certainty of evidence. 
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Before coming to the conclusion that benefits of prophylaxis clearly outweigh 
harm we must, however, consider the uncertainty regarding the baseline risks.  
We reasoned that the conclusion that thromboprophylaxis was clearly warranted 
would require that, even assuming the lowest plausible benefit of pharmacologic 
prophylaxis and the highest plausible harm from bleeding, there would still be a 
net benefit of VTE prophylaxis.  Our challenge then was, for any surgical 
procedure, to provide estimates of the lowest plausible benefit of prophylaxis and 
the associated highest risk of bleeding.  
 
Consider, for instance, patients at high risk of VTE undergoing open radical 
cystectomy – our estimate was 11.6% (the median of the available studies, after 
adjusting for high risk patient category).  Because, in this context, we were 
skeptical of pooled estimates, rather than using a pooled estimate and the 
associated confidence interval, we quantitated imprecision as the range of VTE 
in the available studies – in this case 5.4% to 18.5%.    
 
In terms of other sources of uncertainty, we had no concerns about risk of bias, 
inconsistency, indirectness, or publication bias.  We did, however, lack 
confidence in both the risk stratification, and the model used to infer VTE risk 
when studies did not report the 4-week outcome that was our focus 1 .  In 
qualitative terms, these sources of uncertainty that relate to indirectness led us to 
rate down overall certainty in the evidence regarding VTE from high to moderate. 
 
To judge whether the net benefit of thromboprophylaxis is unequivocally positive 
we need to determine if the smallest plausible benefit in VTE reduction is greater 
than the largest plausible harm for bleeding.  Let us begin with estimating the 
smallest plausible benefit in VTE reduction.  To make this estimate, we must first 
establish the uncertainty in baseline risk associated with imprecision alone – in 
                                         
1 How to classify these sources of uncertainty in the GRADE framework is not 
altogether clear.  Risk of bias and indirectness would both be candidates. 
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this case suggesting a lowest plausible baseline risk of VTE of 5.4% (the Table 
presents this, and all subsequent calculation results). 
 
Next – and here we come to the point of this article - we need to quantify the 
uncertainty associated with risk stratification and model inferences, and thus 
establish an uncertainty range.  We specified, arbitrarily, that each non-
quantitative reason for rating down quality of evidence would (relatively) widen 
the certainty range by 20%.   
 
There could be a number of ways of applying this 20% inflation; our approach 
was as follows.  We took the difference between the point estimate of baseline 
risk of VTE (in this case 11.6%) and the lower limit based on imprecision alone 
(in this case 5.4%) and calculated the difference – here, 6.2%.  We increased 
this difference by 20%, multiplying by 1.2 (20% increase to from 6.2% to 7.4%)2.  
To obtain the new lower limit of plausible baseline risk we subtracted this value – 
7.4% - from the point estimate (11.6% - 7.4%); the new lower limit of baseline 
risk in this case was therefore 4.2%.  Since pharmacologic prophylaxis reduces 
the relative risk of VTE by 50%, the smallest possible benefit for high VTE risk 
patients undergoing cystectomy is 2.1%. 
 
Applying the same logic to bleeding requiring reoperation undergoing cystectomy, 
our best estimate of bleeding was 0.3%, with a range of 0 to 1.6%.  We once 
again rated down for model uncertainty.  To do so quantitatively, we took the 
difference between the point estimate and upper confidence boundary (1.6% - 
0.3% = 1.3%), multiplied by 1.2 to 1.6%, and added this to 0.3% for an upper 
boundary of 1.9%. However, as approximately 50% of major bleeds occur 
between surgery and the next morning but cumulative risk of VTE during the first 
four weeks post-surgery is almost constant, and as – because of mentioned 
differences in the timing of risks of VTE and bleeding - our recommendations for 
pharmacological prophylaxis were based on a starting time of the morning after 
                                         
2 Calculations are, where possible, rounded to a single decimal place. 
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surgery, the baseline risk of bleeding was only half of that 1.9%. Therefore, as 
the increase in bleeding with prophylaxis is half of this 1.0%, but because 
bleeding has double the disutility of VTE, we can consider the negative value of 
the bleeding 1.0% - this however, is still less than the value of VTE reduction of 
2.1% (Table).   
 
Thus, the smallest possible net benefit (value of the smallest reduction in VTE of 
2.1% - value of the largest increase in bleeding of 1.0%) is still positive, 1.1%.  
Given that this is the case, we assumed that we had high certainty evidence for 
the benefit of thromboprophylaxis in high VTE risk patients undergoing open 
radical cystectomy because the concerns about baseline risk estimates that led 
us to rating down for indirectness are mitigated by this sensitivity analysis. Thus 
we decided to retain the certainty of evidence regarding baseline risk of both VTE 
and bleeding at high. 
 
The Table presents the results of the high-risk cystectomy example we have just 
worked through, as well as low and moderate risk of cystectomy, and another 
example, laparoscopic partial nephrectomy, in which we applied the approach. 
Figure 2 depicts the expansion of the lower boundary of laparoscopic partial 
nephrectomy. Even after rating down twice (expanding the range 20% both 
times) the net benefit remains positive in the high-risk group, thus increasing our 
conviction that the benefits of thromboprophylaxis outweigh the harms.   
 
In the work we described above, we focused exclusively on issues of the 
certainty of baseline risk, assuming that we had no concerns regarding relative 
effect estimates.  Thus, we made no attempt to address the integration of 
baseline and relative risk judgments.  In the following we speculate on how 
GRADE might approach such integration. 
 
 
Judging Certainty of Evidence of Intervention Effects 
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Our discussion to this point has focused on the impact of the certainty of the 
evidence regarding baseline risks on net benefit.  GRADE requires a rating of 
certainty regarding absolute effects of treatment – the absolute effects are 
influenced both by the relative effects of treatment and by the baseline risk (also 
referred to as the control event rate).  Prior GRADE discussions of making 
judgments about certainty of absolute effects has focused on the certainty of the 
estimates of relative effect, with very little discussion of the certainty of baseline 
risk, the focus of this article.  Moreover, the GRADE working group has not yet 
written about incorporating the uncertainties regarding baseline risk with the 
uncertainties regarding relative effects.  The following, therefore, represents 
speculation regarding how GRADE might in future address the issue. 
 
How should one integrate certainty ratings of baseline risk with certainty ratings 
of relative effect?  One of the GRADE domains applied to rating certainty of 
relative effects is indirectness that includes indirectness of the population, the 
intervention, the comparator and the outcome, as well as indirect comparisons.  
One might consider uncertainty regarding the baseline risk as an issue of 
indirectness of the population (Figure 3).  In this conceptualization, uncertainty 
about baseline risk leaves us unsure about the population to whom the baseline 
risk we have generated applies (if indeed, it applies to any population – it may, 
for instance, be biased, and though we may still use that baseline risk, we would 
do so with reservations).   
 
Using this approach, one might, in making judgments regarding certainty of the 
absolute effect, rate down for indirectness of the population if the certainty of the 
baseline risk was low or very low, and not rate down if the certainty of baseline 
risk was moderate or high.  Applying such an approach to the current discussion, 
when certainty prior to considering the extent of overlap between certainty 
ranges of value-adjusted certainty of thrombosis and bleeding was moderate or 
low, and the certainty ranges suggest clear benefit or harm, one would not rate 
down certainty of the evidence regarding the absolute effect of prophylaxis 
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because of uncertainty of baseline risk.  In other situations (very low quality 
evidence, or low quality and certainty ranges do not indicate clear benefit or 
harm), one would rate down the certainty of the evidence regarding the absolute 
effect of treatment because of indirectness of the population.    
 
 
Discussion 
This study represents our first foray into utilizing the concept of the certainty 
range to place a quantitative estimate on domains of uncertainty (risk of bias, 
inconsistency, indirectness, publication bias) that, within the GRADE framework, 
are up to now addressed only qualitatively (3).   We applied these quantitative 
estimates to the baseline risk of VTE and bleeding risk in patients undergoing 
urological surgery and in doing so established whether inferences regarding the 
net benefits of pharmacologic prophylaxis were secure.  In some instances we 
found they were secure (Table), and in others they were not.   
 
Strengths of this work includes the rigorous systematic review methodology 
applied to baseline risk estimates of VTE and bleeding in urological surgery and 
the application of the logic of uncertainty ranges to these real life examples.  The 
practical application, despite the arbitrariness of the magnitude and distribution 
assumptions of the certainty ranges, presents an important strength of this work, 
which has previously not been done in any detail. Further, the results have been 
incorporated in clinical practice guidelines for the use of thromboprophylaxis in 
urological surgery (4).  Additional strengths include the grounding of our 
approach within the widely used GRADE framework and, as a result, the 
consideration of all major domains of uncertainty. 
 
The primary limitation of our work is inherent in the uncertainty range approach at 
this point (3). There is a great deal of arbitrariness in the decision regarding the 
quantitation of uncertainty of domains other than precision, in particular risk of 
bias, indirectness, and publication bias.  We could have, but did not, address this 
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uncertainty to some extent through more extensive sensitivity analysis.  For 
instance, we could have examined the impact on our inferences of increasing the 
range of plausible truth for each domain of uncertainty beginning at 10% and 
increasing to 50% or even more.  Some might find our examples more 
compelling had we used data amenable to conventional meta-analysis, and 
addressed an issue of relative effects rather than baseline risk.  Our primary 
purpose, however, was to illustrate the essential concept, and our data serves 
that purpose well. 
 
In terms of prior work, one could argue that those using random effect models, in 
which confidence intervals are inflated by between-study differences in effect, are 
applying a quantitative measure of uncertainty related to inconsistency.  
GRADE’s position on the matter has been that this widening of the confidence 
intervals does not fully address inconsistency.   
 
Formal decision analytic models sometimes do address issues of imprecision, 
inconsistency and indirectness of populations quantitatively through sensitivity 
analysis.  Thus far they have not, however, done so with respect to indirectness 
and, to a limited degree, with respect to risk of bias, nor have they expressed 
results explicitly using the concept of the uncertainty range. 
  
Our primary purpose in presenting this work is to further highlight the concept of 
the uncertainty range and the potential for ultimate quantitation of all domains of 
uncertainty (3).  We look forward to others’ work in taking these concepts forward. 
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Table 1. Calculations resulting in certainty ranges. 
 
Procedure Number 
of quality 
domains 
with 
serious 
problems 
Initial 
lowest 
estimate 
of the 
baseline 
VTE risk 
The lowest 
estimate of 
the baseline 
VTE risk 
adjusted for 
uncertainty* 
Benefit of 
VTE 
prophylaxis 
(decrease 
in VTE)† 
Initial 
highest 
estimate 
of the 
baseline 
bleeding 
risk  
Highest 
estimate of 
the baseline 
bleeding 
risk 
adjusted for 
uncertainty* 
Harm of 
VTE 
prophylaxis 
(increase in 
bleeding)†  
Lowest 
plausible 
net 
benefit‡ 
Decision 
re-rating 
up§ 
Open radical cystectomy 
    
 Low 
risk 
One 1.3% 1.0% 0.5% 1.6% 1.9% 0.5% -0.4% Do not 
rate up 
 Medium 
risk 
One 2.7% 2.1% 1.0% 1.6% 1.9% 0.5% 0.1% Rate up 
 High 
risk 
One 5.4% 4.1% 2.1% 1.6% 1.9% 0.5% 1.1% Rate up 
Laparoscopic partial nephrectomy 
 Low 
risk 
Two 0.9% 0.8% 0.4% 2.3% 2.6% 0.6% -0.9% Do not 
rate up 
 Medium 
risk 
Two 1.8% 1.6% 0.8% 2.3% 2.6% 0.6% -0.5% Do not 
rate up 
 High 
risk 
Two 3.2% 3.0% 1.5% 2.3% 2.6% 0.6% 0.2% Rate up 
* Value after widening certainty interval by 20% for each domain (risk of bias, inconsistency, indirectness, publication bias) with 
serious problems warranting rating down the certainty of the evidence.  
† Our recommendations for pharmacological prophylaxis were based on a starting time of the morning after surgery (4).  
Approximately 50% of major bleeds occur between surgery and the next morning. In contrast, cumulative risk of VTE during the first 
four weeks post-surgery is constant (5).  
‡ Net benefit is equal to absolute reduction in VTE risk minus absolute increase in bleeding risk (with twice the weight for major 
bleeding as for VTE). The net benefit is positive when the value of reduced VTE is greater than increased bleeding. 
§ Decision to rate up only if lowest plausible net benefit positive; that is, if difference after valuation greater than 0. 
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